Hon ANDREW LITTLE: Therapeutic treatments will only become available to the public once Medsafe has completed their approval process. Tocilizumab and remdesivir are approved by Medsafe for use in New Zealand for other purposes than COVID-19, but currently Medsafe is considering their approval process for those drugs for COVID-19. Molnupiravir, Ronapreve, and baricitinib are yet to be approved. All are currently undergoing the Medsafe approval process. However, it is important that we continue pursuing purchases ahead of the approval process to ensure availability as soon as possible, something that I know the Opposition has been concerned about in relation to other treatments. For example, Pharmac expects to receive 500 doses of baricitinib this month, which is important because there's a global shortage of tocilizumab, and this gives clinicians another option. We've also secured 60,000 courses of molnupiravir as well as enough doses of Ronapreve to be able to treat 5,300 people, and we expect to be able to buy more next year.